{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:08:35Z","timestamp":1792112915937,"version":"4.4.0"},"reference-count":42,"publisher":"Akademiai Kiado Zrt.","issue":"3","content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["J Behav Addict"],"published-print":{"date-parts":[[2018,9,21]]},"abstract":"<jats:sec sec-type=\"background and aims\">\n          <jats:title>Background and aims<\/jats:title>\n          <jats:p>To investigate the potential indications and adverse effects of using the opioid antagonist naltrexone to treat problem gamblers.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec sec-type=\"case presentation\">\n          <jats:title>Case presentation<\/jats:title>\n          <jats:p>The files of the 1,192 patients who were referred to the National Problem Gambling Clinic between January 2015 and June 2016 were audited. Seventeen patients were considered appropriate for treatment with naltrexone, having attended and failed to respond to psychological therapies at the clinic. Fourteen patients were placed on a regimen of 50\u00a0mg\/day naltrexone.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec sec-type=\"discussion\">\n          <jats:title>Discussion<\/jats:title>\n          <jats:p>Of the 14 patients who were treated with naltrexone, there were 10 for whom sufficient follow-up existed to analyze the treatment efficacy and side effects of naltrexone. Patients showed significant decreases in their craving to gamble and the majority (60%) were able to abstain completely from gambling in the treatment period, with a further 20% reducing their gambling to almost nothing. The reported side effects from the naltrexone included: loss of appetite, gastrointestinal pain, headaches, sedation, dizziness, and vivid dreams. Two patients with concurrent alcohol-use disorder relapsed during the treatment. One patient relapsed after the treatment period.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec sec-type=\"conclusions\">\n          <jats:title>Conclusions<\/jats:title>\n          <jats:p>The study showed significant outcomes in reducing gambling cravings for the sample set. Given the design of the study as a case series, there was no control group, and a number of patients were on other psychotropic medications. We recommend care when prescribing to those suffering from concurrent alcohol-use disorder.<\/jats:p>\n        <\/jats:sec>","DOI":"10.1556\/2006.7.2018.89","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T12:22:02Z","timestamp":1538742122000},"page":"827-833","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":27,"title":["The use of naltrexone in pathological and problem gambling: A UK case series"],"prefix":"10.1556","volume":"7","author":[{"given":"Sophie","family":"Ward","sequence":"first","affiliation":[{"name":"1 National Problem Gambling Clinic, Central and North West London NHS Foundation Trust, London, UK"},{"name":"2 Institute of Medical and Biomedical Education, St. George\u2019s University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Smith","sequence":"additional","affiliation":[{"name":"1 National Problem Gambling Clinic, Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrietta","family":"Bowden-Jones","sequence":"additional","affiliation":[{"name":"1 National Problem Gambling Clinic, Central and North West London NHS Foundation Trust, London, UK"},{"name":"3 Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref491","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.nmd.0000142021.71880.ce","article-title":"Gambling and suicidality in treatment-seeking pathological gamblers","volume":"192","author":"Ledgerwood","year":"2004","journal-title":"The Journal of Nervous and Mental Disease,"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/070674379804300104","article-title":"Naltrexone in the treatment of pathological gambling and alcohol dependence","volume":"43","author":"Crockford","year":"1998","journal-title":"The Canadian Journal of Psychiatry,"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004850-200109000-00006","article-title":"An open naltrexone treatment study in pathological gambling disorder","volume":"16","author":"Kim","year":"2001","journal-title":"International Clinical Psychopharmacology,"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","article-title":"Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling","volume":"49","author":"Kim","year":"2001","journal-title":"Biological Psychiatry,"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/070674371305800502","article-title":"Phenomenology and treatment of behavioural addictions","volume":"58","author":"Grant","year":"2013","journal-title":"Canadian Journal of Psychiatry,"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000435876","article-title":"A randomized, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling","volume":"22","author":"Kovanen","year":"2016","journal-title":"European Addiction Research,"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40263-016-0373-0","article-title":"Naltrexone: A pan-addiction treatment?","volume":"30","author":"Aboujaoude","year":"2016","journal-title":"CNS Drugs,"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/13651500310003219","article-title":"Three cases of compulsive buying treated with naltrexone","volume":"7","author":"Grant","year":"2003","journal-title":"International Journal of Psychiatry in Clinical Practice,"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1023057027992","article-title":"Alcohol consumption and self-control of gambling behaviour","volume":"15","author":"Baron","year":"1999","journal-title":"Journal of Gambling Studies,"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/jcp.0b013e31815a4400","article-title":"12-month follow up study of drug treatment in pathological gamblers: A primary outcome study","volume":"27","author":"Dannon","year":"2007","journal-title":"The Journal of Clinical Psychopharmacology,"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.v62n1207","article-title":"Demographic and clinical features of 131 adult pathological gamblers","volume":"62","author":"Grant","year":"2001","journal-title":"Journal of Clinical Psychiatry,"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004850-200109000-00006","article-title":"An open naltrexone treatment study in pathological gambling disorder","volume":"16","author":"Kim","year":"2001","journal-title":"International Clinical Psychopharmacology,"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/13651500310003219","article-title":"Three cases of compulsive buying treated with naltrexone","volume":"7","author":"Grant","year":"2003","journal-title":"International Journal of Psychiatry in Clinical Practice,"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1192\/bjp.bp.110.078105","article-title":"Nalmefene in the treatment of pathological gambling: Multi-centre, double-blind, placebo-controlled study","volume":"197","author":"Grant","year":"2010","journal-title":"The British Journal of Psychiatry,"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"The American Journal of Psychiatry,"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v69n0511","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges","volume":"69","author":"Grant","year":"2008","journal-title":"Journal of Clinical Psychiatry,"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.biopsych.2008.11.022","article-title":"A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania","volume":"65","author":"Grant","year":"2009","journal-title":"Biological Psychiatry,"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2125.2012.04457.x","article-title":"Pharmacological treatments in pathological gambling","volume":"77","author":"Grant","year":"2014","journal-title":"British Journal of Clinical Pharmacology,"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.npp.1300101","article-title":"A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: Naltrexone and nalmefene","volume":"28","author":"Drobes","year":"2003","journal-title":"Neuropsychopharmacology,"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/009127009703700105","article-title":"Safety and tolerance of methylnaltrexone in healthy humans: A randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study","volume":"37","author":"Foss","year":"1997","journal-title":"Journal of Clinical Pharmacology,"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2125.2012.04457.x","article-title":"Pharmacological treatments in pathological gambling","volume":"77","author":"Grant","year":"2014","journal-title":"British Journal of Clinical Pharmacology,"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study","volume":"62","author":"Grant","year":"2007","journal-title":"Biological Psychiatry,"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40263-016-0373-0","article-title":"Naltrexone: A pan-addiction treatment?","volume":"30","author":"Aboujaoude","year":"2016","journal-title":"CNS Drugs,"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/009127009703700105","article-title":"Safety and tolerance of methylnaltrexone in healthy humans: A randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study","volume":"37","author":"Foss","year":"1997","journal-title":"Journal of Clinical Pharmacology,"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.biopsych.2008.11.022","article-title":"A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania","volume":"65","author":"Grant","year":"2009","journal-title":"Biological Psychiatry,"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v69n0511","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges","volume":"69","author":"Grant","year":"2008","journal-title":"Journal of Clinical Psychiatry,"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/S0140-6736(10)62185-X","article-title":"Gambling disorders","volume":"378","author":"Hodgins","year":"2011","journal-title":"Lancet,"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study","volume":"62","author":"Grant","year":"2007","journal-title":"Biological Psychiatry,"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/070674371305800502","article-title":"Phenomenology and treatment of behavioural addictions","volume":"58","author":"Grant","year":"2013","journal-title":"Canadian Journal of Psychiatry,"},{"key":"ref481","first-page":"35","article-title":"Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: A pilot study","volume":"43","author":"Lahti","year":"2010","journal-title":"Psychopharmacology Bulletin,"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/jcp.0b013e31815a4400","article-title":"12-month follow up study of drug treatment in pathological gamblers: A primary outcome study","volume":"27","author":"Dannon","year":"2007","journal-title":"The Journal of Clinical Psychopharmacology,"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.nmd.0000142021.71880.ce","article-title":"Gambling and suicidality in treatment-seeking pathological gamblers","volume":"192","author":"Ledgerwood","year":"2004","journal-title":"The Journal of Nervous and Mental Disease,"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.v62n1207","article-title":"Demographic and clinical features of 131 adult pathological gamblers","volume":"62","author":"Grant","year":"2001","journal-title":"Journal of Clinical Psychiatry,"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/S0140-6736(10)62185-X","article-title":"Gambling disorders","volume":"378","author":"Hodgins","year":"2011","journal-title":"Lancet,"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.npp.1300101","article-title":"A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: Naltrexone and nalmefene","volume":"28","author":"Drobes","year":"2003","journal-title":"Neuropsychopharmacology,"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"The American Journal of Psychiatry,"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/070674379804300104","article-title":"Naltrexone in the treatment of pathological gambling and alcohol dependence","volume":"43","author":"Crockford","year":"1998","journal-title":"The Canadian Journal of Psychiatry,"},{"key":"ref231","first-page":"35","article-title":"Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: A pilot study","volume":"43","author":"Lahti","year":"2010","journal-title":"Psychopharmacology Bulletin,"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000435876","article-title":"A randomized, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling","volume":"22","author":"Kovanen","year":"2016","journal-title":"European Addiction Research,"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","article-title":"Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling","volume":"49","author":"Kim","year":"2001","journal-title":"Biological Psychiatry,"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1023057027992","article-title":"Alcohol consumption and self-control of gambling behaviour","volume":"15","author":"Baron","year":"1999","journal-title":"Journal of Gambling Studies,"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1192\/bjp.bp.110.078105","article-title":"Nalmefene in the treatment of pathological gambling: Multi-centre, double-blind, placebo-controlled study","volume":"197","author":"Grant","year":"2010","journal-title":"The British Journal of Psychiatry,"}],"container-title":["Journal of Behavioral Addictions"],"original-title":[],"link":[{"URL":"https:\/\/www.akademiai.com\/doi\/full-xml\/10.1556\/2006.7.2018.89","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/2006\/7\/3\/article-p827.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/2006\/7\/3\/article-p827.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:59:21Z","timestamp":1634173161000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/2006\/7\/3\/article-p827.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":42,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/2006.7.2018.89","relation":{},"ISSN":["2062-5871","2063-5303"],"issn-type":[{"value":"2062-5871","type":"print"},{"value":"2063-5303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}